Europe Oligonucleotide Synthesis Market Segmented By Product (Primer, Probe, Linker, Adaptor, Custom, Reagent, Equipment), Application (PCR, DNA, RNAi, Research, Therapeutic), End-User (Academic, Pharmaceutical, Biotechnology), And Region- Forecast to (2025 to 2033)
The Europe oligonucleotide synthesis market size was calculated at USD 1.05 billion in 2024 and is anticipated to reach USD 3.52 billion by 2033, from USD 1.20 billion in 2025, growing at a CAGR of 14.4% during the forecast period.
Oligonucleotide synthesis is the chemical process of constructing short sequences of nucleic acids and is commonly used as primers, probes, or therapeutic agents in molecular biology, diagnostics, and drug development. Within Europe, this market is distinguished by its integration into advanced genomic research, precision medicine initiatives, and the expanding pipeline of nucleic acid–based therapeutics. A growing number of oligonucleotide-based drugs have received marketing authorisation or entered late-stage clinical development globally. Europe hosts a substantial share of ongoing antisense oligonucleotide trials and accounts for a significant portion of academic publications related to nucleic acid therapeutics, which is indicative of its strong research and development ecosystem. According to the European Commission’s 2024 EU Industrial R&D Investment Scoreboard, the health industries invested about €258.1 billion in R&D in 2023, which is substantially higher than earlier estimates. The convergence of rising demand for personalised oncology treatments, the proliferation of CRISPR and RNA interference technologies, and sustained biopharmaceutical R&D expenditures positions oligonucleotide synthesis as a critical enabler of next-generation healthcare solutions in Europe.
The growing integration of oligonucleotide-based therapeutics into mainstream clinical pathways is primarily driving the growth of the oligonucleotide synthesis market in Europe. Unlike traditional small-molecule drugs, these agents, including antisense oligonucleotides, siRNA, and aptamers, offer precise modulation of gene expression, which makes them particularly valuable in treating rare genetic disorders and certain cancers. A growing number of oligonucleotide-based drugs have received marketing authorisation by the European Medicines Agency or entered Phase II/III trials across Europe. Conditions such as spinal muscular atrophy and hereditary transthyretin amyloidosis, which collectively affect tens of thousands of patients across the EU, now have oligonucleotide-based treatment options, which are driving consistent manufacturing demand. Moreover, the Horizon Europe programme, which spans 2025 to 2033, has allocated multibillion-euro funding to RNA therapeutics and genomic medicine projects, which are accelerating translational research and directly increasing reliance on high-purity custom oligonucleotides. Germany alone hosts over a hundred biotech firms actively developing nucleic-acid therapeutics, which is reinforcing regional synthesis infrastructure needs. The clinical validation of these modalities not only expands patient access but also institutionalises oligonucleotide synthesis as a non-discretionary component of Europe’s biopharmaceutical supply chain.
The proliferation of genomic sequencing and molecular diagnostics across European healthcare systems has significantly intensified demand for synthetic oligonucleotides as essential reagents and is contributing to the expansion of the European market. These short nucleic acid strands serve as primers and probes in polymerase chain reaction, next-generation sequencing, and fluorescence in situ hybridization techniques now routinely deployed in oncology, infectious disease surveillance, and prenatal screening. A growing number of clinical laboratories in the European Union use oligonucleotide-based assays for pathogen detection or cancer biomarker identification. The 1+ Million Genomes Initiative, a cross-border EU effort to enable secure access to genomic and health data, has already begun implementing a federated infrastructure that mandates large-scale sequencing infrastructure, which is increasing demand for millions of custom oligonucleotides annually. In the UK, the Wellcome Sanger Institute-led whole-genome sequencing of 500,000 participants relies on high-throughput oligonucleotide synthesis for library preparation and target enrichment. France’s Plan France Médecine Génomique 2025, aiming to sequence 600,000 genomes by 2025, further amplifies this demand. These publicly funded genomic programmes create a sustained and predictable consumption base for synthetic oligonucleotides, which embeds them deeply within Europe’s precision-medicine ecosystem.
The European Union imposes some of the world’s most rigorous quality and safety standards for oligonucleotide-based products, which significantly elevates manufacturing complexity and cost and hinders the growth of the European oligonucleotide synthesis market. Under the European Medicines Agency’s guidelines for advanced therapy medicinal products, synthetic oligonucleotides intended for therapeutic use must adhere to Good Manufacturing Practice protocols that include full traceability of raw materials, extensive batch testing, and validation of impurity profiles. As per the EMA’s 2023 reflection paper on oligonucleotide impurities, manufacturers are required to identify and quantify deletion sequences, depurination byproducts, and phosphorothioate diastereomers. Development timelines often extend by 6 to 12 months, and production costs increase by 30% to 50% compared to research-grade synthesis. The Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) regulation mandates comprehensive environmental risk assessments for certain phosphoramidite reagents, which constrains supply-chain flexibility. Facilities in Europe must hold dual certification when supplying diagnostics and therapeutics simultaneously, which limits smaller synthesis providers and concentrates market access among a few vertically-integrated players, thereby reducing competitive pricing and scalability.
Establishing and maintaining state-of-the-art oligonucleotide synthesis infrastructure in Europe entails substantial capital investment and recurring operational costs that act as another significant restraint to the regional market growth. Modern high-throughput platforms capable of producing long or chemically modified oligonucleotides (for example, incorporating 2′-O-methyl or locked nucleic acid chemistries) often require automated synthesizers that sit at the higher end of capital expenditure for the industry. The global equipment market for oligonucleotide synthesis systems is anticipated to grow promisingly over the forecast period. In addition, the integration of in-line real-time analytics (such as mass spectrometry or capillary electrophoresis) raises the cost and complexity of production lines. For example, facilities must also invest in ultra-pure solvents and maintain controlled-environment suites that require significant maintenance and operational expenditures. Efforts by institutions such as the Fraunhofer Institute for Manufacturing Engineering and Automation show ongoing investment in contamination-critical cleanroom infrastructure. Moreover, the shortage of specialised bioprocess engineers and technicians adds to the operational burden. As a result, many academic and mid-sized biotech organisations outsource oligonucleotide synthesis, which is a dependency that introduces supply-chain risk and pricing volatility. The high barrier to entry in this sector tends to concentrate manufacturing among a limited number of vertically-integrated players that can limit competitive pricing and flexibility.
The convergence of artificial intelligence and synthetic biology is a promising opportunity for the European oligonucleotide synthesis market by dramatically improving sequence design accuracy and manufacturing efficiency. Machine-learning algorithms can now predict off-target effects, secondary structures, and nuclease susceptibility of candidate oligonucleotides before synthesis, reducing experimental failure rates. Companies such as Owlet Technologies (Switzerland) and Nuclera (United Kingdom) have deployed proprietary AI platforms that couple thermodynamic modelling with empirical synthesis to yield data to optimise phosphoramidite-coupling cycles in real time. This digital integration shortens lead times from weeks to days for custom orders and enhances purity consistency, which is critical for therapeutic applications. The European Innovation Council (EIC) awarded grant funding to AI biotech startups focusing on nucleic-acid design under the Horizon Europe framework. Furthermore, the EU’s Digital Europe Programme has funded pilot projects in Germany and the Netherlands to establish cloud-based oligonucleotide design hubs accessible to SMEs, which is democratising access to advanced computational tools. As AI models are trained on Europe’s rich repository of genomic and clinical data that is protected under the General Data Protection Regulation (GDPR) but enabled through federated-learning frameworks, they can generate region-specific design insights that improve therapeutic efficacy and patient stratification, thereby expanding the addressable market for precision oligonucleotides.
The emergence of compact, bench-top oligonucleotide synthesizers is catalyzing a shift toward decentralized production models across European research and clinical institutions, which is unlocking new market opportunities. Unlike traditional centralized facilities that require bulk orders and extended turnaround times, these next-generation instruments, such as those developed by DNA Script and BioXp, can produce microgram to milligram quantities of custom sequences within hours using enzymatic or electrochemical synthesis methods. In recent years, dozens of European university hospitals and core genomics laboratories have installed on-site synthesizers to support rapid-response applications, including pathogen-probe development and intraoperative cancer margin detection. During the 2022 Mpox outbreak, Institut Pasteur in France developed diagnostic primers in an unusually short time using an in-house platform, which would have been difficult via conventional supply chains. The European Commission’s Strategic Plan for Health Research encourages point-of-need nucleic-acid manufacturing to bolster health security. As regulatory frameworks adapt to accommodate smaller-scale GMP-compliant units, more hospitals and biotech incubators are expected to adopt on-demand synthesis, thereby creating a fragmented but potentially high-growth niche within the broader European market.
The European oligonucleotide synthesis market remains acutely exposed to disruptions in the supply of high-purity phosphoramidites, controlled pore glass solid supports, and specialty solvents that most of which are sourced from a narrow base of non-European suppliers, which is one of the significant challenges to the European market. Europe remains heavily dependent on imported phosphoramidite monomers and specialty reagents for oligonucleotide synthesis, which became especially evident during the 2022 global acetonitrile shortage. Such supply-chain disruptions expose the vulnerability of regional manufacturing continuity. Additionally, geopolitical tensions and export-control measures affecting nucleotide-precursor chemistry complicate long-term procurement planning. Although the EU Critical Raw Materials Act currently does not classify nucleic-acid-synthesis reagents as strategic, domestic production capabilities within Europe remain limited, effectively forcing many manufacturers to hold elevated safety stocks and increasing the cost burden. Until Europe diversifies its reagent sourcing or scales indigenous production, synthesis continuity will remain exposed to external shocks.
The commercial viability of oligonucleotide-based drugs in Europe is impeded by fragmented and inconsistent reimbursement policies across member states, which is another major challenge to the expansion of the oligonucleotide synthesis market in Europe. Unlike the centralized approval process of the European Medicines Agency, pricing and reimbursement decisions are made independently by national health technology assessment bodies that resulting in wide disparities in patient access and market predictability. Several European countries fully reimburse Nusinersen (for Spinal Muscular Atrophy), but access remains uneven across the continent. The resulting patchwork discourages manufacturers from investing in large-scale synthesis capacity dedicated to the European market, as revenue projections become highly uncertain. According to studies, the time from European Medicines Agency approval to national reimbursement in the EU varies significantly between countries. For example, one 2023 study revealed median reimbursement times of 3 days in Germany vs. 142 days in France for novel anticancer drugs. Furthermore, cost-effectiveness thresholds differ drastically between countries, complicating the justification of high production costs for personalised oligonucleotide therapies. Without a coordinated EU-level value assessment mechanism, such as the proposed joint clinical assessment under the Pharmaceutical Strategy for Europe, developers face a fragmented commercial landscape that constrains investment in synthesis infrastructure and limits patient reach.
| REPORT METRIC | DETAILS |
| Market Size Available | 2024 to 2033 |
| Base Year | 2024 |
| Forecast Period | 2025 to 2033 |
| CAGR | 14.4% |
| Segments Covered | By Product, Application, End Use Industry, And Region |
| Various Analyses Covered | Global, Regional & Country Level Analysis; Segment-Level Analysis; DROC, PESTLE Analysis; Porter’s Five Forces Analysis; Competitive Landscape; Analyst Overview of Investment Opportunities |
| Regions Covered | UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, and the Czech Republic |
| Market Leaders Profiled | Agilent Technologies, Inc., Atdbio Ltd., LGC Limited, Bio-Synthesis Inc., Eurofins Genomics, Kaneka Eurogentec S.A., And General Electric |
The Europe oligonucleotide synthesis market features intense competition among specialized CROs, large life science conglomerates, and agile biotech innovators. The landscape is characterized by a dual focus on scale and customization, where established players leverage manufacturing infrastructure while niche firms compete on technical expertise in modified sequences. Competition is not solely price-driven but centers on purity assurance, turnaround speed, regulatory compliance, and support for complex chemistries. Companies differentiate through integrated service models that combine synthesis with analytical validation, sequencing, and formulation. The market also sees rising rivalry in decentralized synthesis technologies, with several firms racing to deploy benchtop platforms across academic and clinical sites. Barriers to entry remain high due to capital intensity and regulatory complexity, yet innovation in enzymatic synthesis and AI-driven design is enabling new entrants to carve disruptive niches. Overall, the competitive dynamic favors those who balance scientific depth with operational agility.
A few major players of the Europe oligonucleotide synthesis market include
Key players in the Europe oligonucleotide synthesis market prioritize vertical integration to control raw material supply and ensure reagent purity. They invest heavily in automated high-throughput synthesis platforms to improve yield and reduce human error. Strategic collaborations with academic and clinical institutions accelerate the co-development of novel therapeutic sequences. Companies are expanding GMP-compliant manufacturing footprints to meet rising demand for clinical-grade oligonucleotides. Digital transformation initiatives, including cloud-based order management and real-time analytics, enhance customer experience and operational efficiency. Continuous innovation in modified chemistries such as phosphorodiamidate morpholino oligomers strengthens their service differentiation. Regulatory preparedness through early engagement with the European Medicines Agency streamlines product validation. Lastly, geographic localization of synthesis hubs supports faster delivery and compliance with regional data and safety norms.
Merck KGaA is a pivotal contributor to the Europe oligonucleotide synthesis market through its extensive portfolio of reagents, custom synthesis services, and proprietary synthesis platforms. Headquartered in Darmstadt, Germany, the company serves academic institutions, biotech firms, and pharmaceutical developers across the continent. In recent years, Merck has expanded its GMP-compliant oligonucleotide manufacturing capabilities at its facility in Darmstadt to support clinical and commercial scale production of antisense and siRNA therapeutics. The company also launched its RNApure reagent line in 2023, optimized for high-yield oligonucleotide purification, reinforcing its role as an integrated solutions provider. Its strategic investments in automation and quality control systems underscore its commitment to advancing nucleic acid synthesis standards in Europe and globally.
Eurofins Genomics, a division of the Eurofins Scientific Group, plays a central role in the European oligonucleotide synthesis landscape by offering high-quality custom DNA and RNA synthesis for research and diagnostic applications. Based in Ebersberg, Germany, the company operates one of Europe’s largest synthesis facilities with capabilities spanning standard primers to complex modified oligonucleotides. In 2024, Eurofins Genomics enhanced its itsnext-generationn sequencing support services by introducing ultra-pure barcoded adapters synthesized in-house, catering to the rising demand from genomic medicine initiatives. The company has also integrated digital ordering and real-time tracking systems to streamline client workflows. Its dual focus on scale and precision positions it as a critical enabler of molecular research and diagnostics across Europe and beyond.
ATDBio Ltd, headquartered in Southampton, United Kingdom, is a specialist in the synthesis of complex and highly modified oligonucleotides for therapeutic and diagnostic development. The company is renowned for its expertise in phosphorothioate, 2′ O methyl, and locked nucleic acid chemistries, serving global pharmaceutical and biotech clients from its ISO 13485 certified facility. In 2023, ATDBio expanded its cleanroom capacity and implemented in-line mass spectrometry for real-time quality assurance, significantly reducing turnaround times for GMP-grade sequences. The firm actively collaborates with UK and EU research consortia focused on RNA therapeutics, contributing to early-stage development pipelines. Its niche technical proficiency and agile manufacturing model allow it to address high-value synthesis challenges that larger providers often avoid, reinforcing its strategic relevance in the European ecosystem.
This research report on the Europe oligonucleotide synthesis market has been segmented and sub-segmented based on product, application, end-use industry, and region.
By Product
By Application
By End Use industry
By Region
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from
$ 2000
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: sales@marketdataforecast.com
Reports By Region